Cancer is a major human health challenge and leading cause of death worldwide. There were an estimated 19.3 million new cases and 10 million deaths only in 2020. Strikingly, its incidence and mortality continue to increase worldwide and is projected to increase by 50% in 2040.
Cancer is a multifactorial disease caused by genetic and epigenetic alterations in molecular pathways controlling diverse cellular functions including cell proliferation, differentiation, DNA damage, and cell death. Recent advances in sequencing technologies and bioinformatics have made genetics and genomics key pillars of cancer research and treatment in the pan-cancer era. This has resulted in a wealth of genetic, epigenetic and transcriptomic information that provide further insight into the aetiologia and pathobiology of tumors, treatment and diagnosis. Furthermore, the identification of genetic risk factors with prognostic significance that promote tumor progression and metastasis hold potential clinical relevance to guide clinical decision making.
Although the current advances in cancer treatment and detection are commendable, significant knowledge gaps still exist that must be addressed to enhance our understanding of cancer biology at a population and individual level and create novel therapeutic opportunities for precision medicine.
Areas to be covered in this Research Topic may include, but are not limited to
• Identification of genomic biomarkers for early detection of cancer and treatment response.
• Population-based genomic studies that will help tailoring of treatment plans by ancestry.
• Emerging roles of non-coding RNAs as cancer biomarkers and therapeutic targets for cancer precision medicine.
• Identification of genetic and epigenetic mechanisms of drug resistance that could predict therapy response in a personalized medicine manner.
• Genetic interactions driving tumor initiation, metastatic potential and treatment response.
• Studies addressing risk factors in cancer development, such as lifestyle, environmental exposure to toxins, and co-morbidities.
• Functional genomics studies in patient-derived models for personalized cancer therapy.
• Clinical significance of immunogenomics to guide personalized immunotherapy.
We welcome original research and review articles within the scope of the research topic. Bioinformatic studies are welcome, however, these should not be based solely on analysis of publicly available datasets such as TCGA. It is essential to have an independent validation cohort for statistically significant confirmation of the findings communicated.
Cancer is a major human health challenge and leading cause of death worldwide. There were an estimated 19.3 million new cases and 10 million deaths only in 2020. Strikingly, its incidence and mortality continue to increase worldwide and is projected to increase by 50% in 2040.
Cancer is a multifactorial disease caused by genetic and epigenetic alterations in molecular pathways controlling diverse cellular functions including cell proliferation, differentiation, DNA damage, and cell death. Recent advances in sequencing technologies and bioinformatics have made genetics and genomics key pillars of cancer research and treatment in the pan-cancer era. This has resulted in a wealth of genetic, epigenetic and transcriptomic information that provide further insight into the aetiologia and pathobiology of tumors, treatment and diagnosis. Furthermore, the identification of genetic risk factors with prognostic significance that promote tumor progression and metastasis hold potential clinical relevance to guide clinical decision making.
Although the current advances in cancer treatment and detection are commendable, significant knowledge gaps still exist that must be addressed to enhance our understanding of cancer biology at a population and individual level and create novel therapeutic opportunities for precision medicine.
Areas to be covered in this Research Topic may include, but are not limited to
• Identification of genomic biomarkers for early detection of cancer and treatment response.
• Population-based genomic studies that will help tailoring of treatment plans by ancestry.
• Emerging roles of non-coding RNAs as cancer biomarkers and therapeutic targets for cancer precision medicine.
• Identification of genetic and epigenetic mechanisms of drug resistance that could predict therapy response in a personalized medicine manner.
• Genetic interactions driving tumor initiation, metastatic potential and treatment response.
• Studies addressing risk factors in cancer development, such as lifestyle, environmental exposure to toxins, and co-morbidities.
• Functional genomics studies in patient-derived models for personalized cancer therapy.
• Clinical significance of immunogenomics to guide personalized immunotherapy.
We welcome original research and review articles within the scope of the research topic. Bioinformatic studies are welcome, however, these should not be based solely on analysis of publicly available datasets such as TCGA. It is essential to have an independent validation cohort for statistically significant confirmation of the findings communicated.
